Literature DB >> 10448414

Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modified by recombinant retrovirus.

Y Liu1, B T Himes, J Solowska, J Moul, S Y Chow, K I Park, A Tessler, M Murray, E Y Snyder, I Fischer.   

Abstract

Neural stem cells have been shown to participate in the repair of experimental CNS disorders. To examine their potential in spinal cord repair, we used retroviral vectors to genetically modify a clone of neural stem cells, C17, to overproduce neurotrophin-3 (NT-3). The cells were infected with a retrovirus construct containing the NT-3.IRES.lacZ/neo sequence and cloned by limiting dilution and selection for lacZ expression. We studied the characteristics of the modified neural stem cells in vitro and after transplantation into the intact spinal cord of immunosuppressed adult rats. Our results show that: (i) most of the genetically modified cells express both NT-3 and lacZ genes with a high coexpression ratio in vitro and after transplantation; and (ii) large numbers of the xenografted cells survive in the spinal cord of adult rats for at least 2 months, differentiate into neuronal and glial phenotypes, and migrate for long distances. We conclude that genetically modified neural stem cells, acting as a source of neurotrophic factors, have the potential to participate in spinal cord repair.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448414     DOI: 10.1006/exnr.1999.7079

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  18 in total

Review 1.  Stem cells: cross-talk and developmental programs.

Authors:  Jaime Imitola; Kook In Park; Yang D Teng; Sahar Nisim; Mahesh Lachyankar; Jitka Ourednik; Franz-Josef Mueller; Rene Yiou; Anthony Atala; Richard L Sidman; Mark Tuszynski; Samia J Khoury; Evan Y Snyder
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-05-29       Impact factor: 6.237

Review 2.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

3.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Gene therapy approaches to enhancing plasticity and regeneration after spinal cord injury.

Authors:  Steffen Franz; Norbert Weidner; Armin Blesch
Journal:  Exp Neurol       Date:  2011-01-31       Impact factor: 5.330

5.  In vitro analysis of PNIPAAm-PEG, a novel, injectable scaffold for spinal cord repair.

Authors:  Noelle Comolli; Birgit Neuhuber; Itzhak Fischer; Anthony Lowman
Journal:  Acta Biomater       Date:  2008-10-26       Impact factor: 8.947

6.  Modularity of endpoint force patterns evoked using intraspinal microstimulation in treadmill trained and/or neurotrophin-treated chronic spinal cats.

Authors:  Vanessa S Boyce; Michel A Lemay
Journal:  J Neurophysiol       Date:  2008-12-31       Impact factor: 2.714

Review 7.  Prospects for neural stem cell-based therapies for neurological diseases.

Authors:  Jaime Imitola
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

8.  Recovery of CNS pathway innervating the sciatic nerve following transplantation of human neural stem cells in rat spinal cord injury.

Authors:  Kwang-Bok Lee; Jung Hoon Choi; Kyunghee Byun; Kwang Hoon Chung; Ji Hyeon Ahn; Goo-Bo Jeong; In Koo Hwang; Seungup Kim; Moo-Ho Won; Bonghee Lee
Journal:  Cell Mol Neurobiol       Date:  2011-08-11       Impact factor: 5.046

Review 9.  The state of the art in stem cell biology and regenerative medicine: the end of the beginning.

Authors:  Evan Y Snyder
Journal:  Pediatr Res       Date:  2017-12-13       Impact factor: 3.756

10.  Neurotrophin modulation of voltage-gated potassium channels in rat through TrkB receptors is time and sensory experience dependent.

Authors:  K Tucker; D A Fadool
Journal:  J Physiol       Date:  2002-07-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.